Combination therapy with mutant IDH inhibitors
By using combined therapy of IDH inhibitors, antimetabolic agents, hypomethylating agents and Flt3 inhibitors in AML treatment, the problem of poor efficacy of IDH mutation-related AML treatment in the prior art has been solved, and the effectiveness of the treatment has been significantly improved , especially in the case of resistance mutations and Flt3 kinase mutations.
Patent Information
- Application Number
- CN202180024244.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-20
- Filing Date
- 2021-03-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-03-22
AI Technical Summary
The existing AML treatment methods have limited effect on cancer therapies related to IDH mutations, especially in the presence of IDH resistance mutations and Flt3 kinase mutations, which are difficult to effectively cure.
Using a combination therapy, including the use of one or more mutant isocitrate dehydrogenase (IDH) inhibitors, an metabolic agents and hypomethylating agents, and mutant Flt3 inhibitors, targeting cancers with IDH mutations The patient was treated.
Combination therapy significantly reduces 2-hydroxyglutarate (2-HG) levels, promotes cell differentiation, enhances the inhibitory effect on AML, and improves the effectiveness of treatment, especially in the case of adversarial mutations and Flt3 kinase mutations.
Smart Images

Figure CN115335060B_ABST
Abstract
Description
[0001] The present invention relates to combination therapy using a mutant isocitrate dehydrogenase (IDH) inhibitor and one or more antimetabolites, hypomethylating agents and mutant FMS-like tyrosine kinase 3 (Flt3) inhibitors for the treatment of cancer.
[0002] IDH1 and IDH2 catalyze the conversion of isocitrate to α-ketoglutarate and convert nicotinamide adenine dinucleotide phosphate (NADP + ) is an enzyme that reduces leukemia / lymphocytes to NADPH (Megias-Vericat J et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-32).
[0003] De novo mutations in IDH1, such as at IDH1 amino acid residue R132, contribute to tumorigenesis in several types of cancer, including solid tumor cancers and hematological malignancies (Badur MG et al., Cell Reports 2018; 25: 1680). IDH1 mutations can produce high levels of 2-hydroxyglutarate (2-HG), which inhibits cell differentiation, and inhibitors of mutant IDH1 can reduce 2-HG levels, which promotes cell differentiation (Molenaar RJ et al., Oncogene 2018; 37: 1949-1960). Mutations also occur in IDH2, such as at amino acid residues R172, R140, and R172 (Yang H et al. Clin. Cancer. Res. 2012; 18: 5562-5571; Mondesir J et al., J. Blood Med. 2016; 7: 171-180).
[0004] For example, acute myeloid leukemia (AML) is characterized by a diverse array of mutated genes and a polyclonal genomic structure comprising preleukemic and leukemic clones that evolve dynamically over time and under the selective pressure of therapy (Bloomfield CD et al., Blood Revs. 2018; 32:416-425).
[0005] Induction chemotherapy with cytarabine and anthracyclines ("7+3") has been the standard of care for subjects with newly diagnosed AML for more than four decades.
[0006] In recent years, the U.S. Food and Drug Administration has approved five additional drugs for the treatment of AML: midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin (Bloomfield CD et al., Blood Revs. 2018; 32: 416-425), and ivosidenib (Megias-Vericat J et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-32).
[0007] Approximately 60%-70% of adults with AML can be expected to achieve complete remission (CR) status after appropriate induction therapy, and more than 25% of adults with AML (approximately 45% of those achieving CR) can be expected to survive 3 years or longer and be cured.
[0008] However, IDHL resistance mutations are observed in 7-14% of AML subjects, and the associated high 2-HG levels can produce an epigenetic hypermethylation phenotype and differentiation block, leading to leukemogenesis (Megias-Vericat J et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-3). In addition, mutations in Flt3 kinase are observed in approximately one-third of AML subjects (Lee HJ et al., Oncotarget 2018; 9: 924-936).
[0009] Therefore, there remains a need for alternative therapies for mutant IDH-associated cancers.
[0010] Certain mutant IDH1 and IDH2 inhibitors are disclosed in WO 2018 / 111707 A1, including a compound defined herein as "Compound A", which is a covalent inhibitor of mutant IDH1 that modifies a single cysteine (Cys269) in the allosteric binding pocket, rapidly inactivates the enzyme, and selectively inhibits 2-HG production without affecting (α-KG) levels (WO 2018 / 111707 A1).
[0011] The present invention provides a method for treating cancer, comprising administering to a human cancer subject having an IDH mutation a therapeutically effective amount of a first compound of formula (a):
[0012]
[0013] in:
[0014] R 1is -CH2CH(CH3)2, -CH2CH3, -CH2CH2OCH3 or -CH2-cyclopropyl;
[0015] R 2 is -CH3 or -CH2CH3; and
[0016] X is N or CH;
[0017] or a pharmaceutically acceptable salt thereof; and
[0018] (b) one or more second compounds are an antimetabolite or a pharmaceutically acceptable salt thereof; a hypomethylating agent or a pharmaceutically acceptable salt thereof; and a mutant Flt3 inhibitor or a pharmaceutically acceptable salt thereof.
[0019] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H. In another embodiment, the IDH1 mutation is R132C, R132G, R132L or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.
[0020] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.
[0021] In one embodiment of the method of the present invention, in the first compound of Formula I or a pharmaceutically acceptable salt thereof, X is N. In another embodiment, in the first compound or a pharmaceutically acceptable salt thereof, X is N, R 1 is –CH2-cyclopropyl, and R 2 In another embodiment, in the first compound, X is N, R 1 is –CH2-cyclopropyl, and R2 It is -CH2CH3.
[0022] In another embodiment, the first compound is:
[0023] 7-[[(1S)-1-[4-[(1R)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one;
[0024] 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or
[0025] 1-ethyl-7-[[(1S)-1-[4-[1-(4-prop-2-enoylpiperazin-1-yl)propyl]phenyl]ethyl]amino]-4H-pyrimido[4,5-d][1,3]oxazin-2-one;
[0026] or a pharmaceutically acceptable salt thereof.
[0027] In another embodiment, the first compound is 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one.
[0028] In another embodiment, the first compound is:
[0029]
[0030] or a pharmaceutically acceptable salt thereof.
[0031] In another embodiment, the first compound is Compound A.
[0032] In another embodiment, the subject is identified as having an IDH1 mutation, such as an R132 IDH1 mutation. In another embodiment, the subject is identified as having an IDH2 mutation, such as an IDH2 R172, R140, or R172 mutation. In another embodiment, the subject is identified as having an IDH mutation in a tissue.
[0033] In another embodiment, the cancer is a hematological malignancy and the subject is identified as having an IDH mutation in the blood, bone marrow, lymph nodes, or lymph fluid. In another embodiment, the subject is identified as having an IDH mutation in a blood cell, a bone marrow cell, a lymph node cell, or a lymph fluid cell.
[0034] In another embodiment, the cancer is a solid tumor cancer and the subject is identified as having an IDH1 mutation in the solid tumor tissue. In another embodiment, the subject is identified as having an IDH mutation in a solid tumor tissue cell.
[0035] In another embodiment, the human subject has been identified as having a Flt3 mutation prior to administration of a mutant Flt3 inhibitor. In another embodiment, the Flt3 mutation is a Flt3 internal tandem (Flt3-ITD) mutation. In another embodiment, the Flt3 mutation is a Flt3 tyrosine kinase domain (Flt3-TKD) mutation. In another embodiment, the Flt3 mutation is a Flt3 D835 mutation.
[0036] In another embodiment, the first compound, or a pharmaceutically acceptable salt thereof, is administered prior to the second compound, or a pharmaceutically acceptable salt thereof.
[0037] In another embodiment, the first compound, or a pharmaceutically acceptable salt thereof, is administered after the second compound, or a pharmaceutically acceptable salt thereof.
[0038] In another embodiment, the first compound, or a pharmaceutically acceptable salt thereof, is co-formulated with the second compound, or a pharmaceutically acceptable salt thereof.
[0039] In another embodiment of the method of the present invention, the cancer is a solid tumor cancer. In another embodiment, the solid tumor cancer is cholangiocarcinoma, head and neck cancer, chondrosarcoma, hepatocellular carcinoma, melanoma, pancreatic cancer, astrocytoma, oligodendroglioma, glioma, glioblastoma, bladder cancer, colorectal cancer, lung cancer or sinonasal undifferentiated carcinoma. In another embodiment, lung cancer is non-small cell lung cancer. In another embodiment, lung cancer is non-small cell lung cancer, and α-KR G12C inhibitor and / or EGFR inhibitor are also administered. In another embodiment, the solid tumor cancer is cholangiocarcinoma. In another embodiment, radiotherapy is also administered to the subject.
[0040] In another embodiment, the cancer is a hematological malignancy. In another embodiment, the hematological malignancy is AML (acute myeloid leukemia), myelodysplastic syndrome myeloproliferative tumor, angioimmunoblastic T-cell lymphoma, T-cell acute lymphocytic leukemia, chronic myelogenous leukemia (chronicmyelogenous leukemia), polycythemia vera, essential thrombocythemia (essentialthrombocythemia), primary myelofibrosis or chronic myeloid leukemia. In another embodiment, the hematological malignancy is AML.
[0041] In another embodiment of the method of the present invention, the second compound is an antimetabolite or a pharmaceutically acceptable salt thereof. In another embodiment of the method of the present invention, antimetabolites are cytarabine, 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), capecitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed or photoaminopterin (phototrexate), or a pharmaceutically acceptable salt of any one of them. In another embodiment, antimetabolites are cytarabine or a pharmaceutically acceptable salt thereof. In another embodiment, antimetabolites are cytarabine. In another embodiment, the first compound is compound A, and the second compound is cytarabine. In another embodiment, the cancer is AML, the first compound is compound A, and the second compound is cytarabine. In another embodiment, the cancer is cholangiocarcinoma, the first compound is compound A, and the second compound is cytarabine.
[0042] In another embodiment of the method of the present invention, the second compound is a hypomethylating agent or a pharmaceutically acceptable salt thereof. In another embodiment of the method of the present invention, the hypomethylating agent is azacitidine (5-azacitidine), 5-aza-2'-deoxycytidine (citidine) (Decitabine / Decitabine), guadecitabine (SGI-110), 5-fluoro-2'-deoxycytidine, zebularine, CP-4200, RG108, nanaomycin A, or a pharmaceutically acceptable salt of any one of them. In another embodiment, the hypomethylating agent is azacitidine or a pharmaceutically acceptable salt thereof. In another embodiment, the hypomethylating agent is azacitidine. In another embodiment, the first compound is compound A, and the second compound is azacitidine. In another embodiment, the cancer is AML, the first compound is compound A, and the second compound is azacitidine. In another embodiment, the cancer is cholangiocarcinoma, the first compound is Compound A, and the second compound is azacitidine.
[0043] In another embodiment, the first compound of Formula I or a pharmaceutically acceptable salt thereof is administered together with a hypomethylating agent or a pharmaceutically acceptable salt thereof and a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof. In another embodiment, the first compound of Formula I is administered together with a hypomethylating agent and a Bcl-2 inhibitor. In another embodiment, the Bcl-2 inhibitor is venetoclax, obatoclax, navitoclax, or a pharmaceutically acceptable salt of any one of them. In another embodiment, the Bcl-2 inhibitor is venetoclax or a pharmaceutically acceptable salt thereof. In another embodiment, the Bcl-2 inhibitor is venetoclax. In another embodiment, Compound A is administered together with a hypomethylating agent and a Bcl-2 inhibitor. In another embodiment, Compound A is administered together with azacitidine and venetoclax. In another embodiment, the cancer is AML, and Compound A is administered together with azacitidine and venetoclax. In another embodiment, the cancer is cholangiocarcinoma, and Compound A is administered together with azacitidine and venetoclax.
[0044] In another embodiment of the method of the present invention, the second compound is a mutant Flt3 inhibitor or a pharmaceutically acceptable salt thereof. In another embodiment of the method of the present invention, the mutant Flt3 inhibitor is midostaurin, gilteritinib, quizartinib (AC220), sorafenib, sunitinib, lestaurtinib or crenolanib, or a pharmaceutically acceptable salt of any one of them. In another embodiment, the mutant Flt3 inhibitor is midostaurin or a pharmaceutically acceptable salt thereof. In another embodiment, the mutant Flt3 inhibitor is midostaurin. In another embodiment, the first compound is compound A, and the second compound is midostaurin. In another embodiment, the cancer is AML, the first compound is compound A, and the second compound is midostaurin. In another embodiment, the cancer is cholangiocarcinoma, the first compound is compound A, and the second compound is midostaurin.
[0045] In another embodiment of the methods of the present invention, Compound A is administered with an antimetabolite and a hypomethylating agent.
[0046] In another embodiment of the methods of the present invention, Compound A is administered with an antimetabolite and a mutant Flt3 inhibitor.
[0047] In another embodiment of the methods of the present invention, Compound A is administered with a hypomethylating agent and a mutant Flt3 inhibitor.
[0048] In another embodiment of the methods of the present invention, Compound A is administered with an antimetabolite, a hypomethylating agent, and a mutant Flt3 inhibitor.
[0049] The present invention also provides compounds of formula I:
[0050]
[0051] in:
[0052] R 1 is -CH2CH(CH3)2, -CH2CH3, -CH2CH2OCH3 or -CH2-cyclopropyl;
[0053] R 2 is -CH3 or -CH2CH3; and
[0054] X is N or CH;
[0055] or a pharmaceutically acceptable salt thereof;
[0056] For use in combination with one or more antimetabolites or pharmaceutically acceptable salts thereof; hypomethylating agents or pharmaceutically acceptable salts thereof; or mutant FLT3 inhibitors or pharmaceutically acceptable salts thereof, for treating cancer in human subjects having an IDH mutation.
[0057] In one embodiment, the subject is identified as having an IDH mutation, such as an IDH1 or ID2 mutation, in the blood, bone marrow, lymph nodes, lymph fluid, blood cells, bone marrow cells, lymph node cells, or lymph fluid cells.
[0058] In another embodiment, a compound of Formula I is used in combination with a hypomethylating agent (eg, azacitidine) or a pharmaceutically acceptable salt thereof and a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof to treat cancer in a human subject identified as having an IDH1 R132 mutation.
[0059] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H, R132C, R132G, R132L, or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.
[0060] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.
[0061] In one embodiment, the subject is identified as having an IDH mutation, such as an IDH1 or IDH2 mutation.
[0062] For the compounds of formula I used, preferably X is N, or a pharmaceutically acceptable salt thereof; preferably R 1 is -CH2-cyclopropyl, or a pharmaceutically acceptable salt thereof; preferably R 2 is -CH2CH3, or a pharmaceutically acceptable salt thereof; preferably X is N and R1 is -CH2-cyclopropyl, or a pharmaceutically acceptable salt thereof; preferably R 1 is –CH2-cyclopropyl and R 2 is -CH2CH3, or a pharmaceutically acceptable salt thereof; more preferably X is N, R 1 is –CH2-cyclopropyl and R 2 is -CH2CH3, or a pharmaceutically acceptable salt thereof; most preferably X is N, R 1 is –CH2-cyclopropyl and R 2 It is -CH2CH3.
[0063] Preferred compounds are:
[0064] 7-[[(1S)-1-[4-[(1R)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one;
[0065] 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or
[0066] 1-ethyl-7-[[(1S)-1-[4-[1-(4-prop-2-enoylpiperazin-1-yl)propyl]phenyl]ethyl]amino]-4H-pyrimido[4,5-d][1,3]oxazin-2-one;
[0067] or a pharmaceutically acceptable salt thereof.
[0068] In another embodiment, the first compound is:
[0069]
[0070] (Compound A) or a pharmaceutically acceptable salt thereof.
[0071] In another embodiment, the first compound is Compound A.
[0072] Provided herein is a novel method for treating cancer using a combination of a compound of formula I and one or more antimetabolites, hypomethylating agents or mutant Flt3 inhibitors. Therefore, some aspects of the present invention provide a compound of formula I, which is used to treat a subject with IDH mutation (eg, IDH1 or IDH2 mutation) simultaneously, separately or in combination with one or more of antimetabolites, hypomethylating agents or mutant Flt3 inhibitors. In addition, some aspects of the present invention provide a compound of formula I, which is used to treat solid tumor cancers simultaneously, separately or in combination with one or more of antimetabolites, hypomethylating agents or mutant Flt3 inhibitors. In addition, some aspects of the present invention provide a compound of formula I, which is used to treat hematological malignancies simultaneously, separately or in combination with one or more of antimetabolites, hypomethylating agents or mutant Flt3 inhibitors. Another aspect of the present invention provides a compound of formula I, which is used to treat a subject identified as having IDH mutation (eg, IDH1 or IDH2 mutation) simultaneously, separately or in combination with a hypomethylating agent and a Bcl-2 inhibitor.
[0073] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H, R132C, R132G, R132L, or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.
[0074] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.
[0075] The present invention also provides a pharmaceutical composition comprising a compound of Formula I for use in combination with one or more of the following: an antimetabolite or a pharmaceutically acceptable salt thereof; a hypomethylating agent or a pharmaceutically acceptable salt thereof; or a mutant Flt3 inhibitor or a pharmaceutically acceptable salt thereof, to treat cancer in a human subject identified as having an IDH mutation. In one embodiment, the IDH mutation is identified in blood cells, bone marrow cells, or blood and bone marrow cells.
[0076] The present invention also provides the use of a compound of formula I in the preparation of a drug for treating a cancer in a human subject having an IDH mutation (e.g., an IDH1 or IDH2 mutation). In one embodiment, the subject is identified as having an IDH mutation in blood, bone marrow, lymph nodes, lymph fluid, blood cells, bone marrow cells, lymph node cells, or lymph fluid cells, wherein the compound of formula I for the preparation of the drug is administered in combination with one or more antimetabolites or a pharmaceutically acceptable salt thereof; a hypomethylating agent or a pharmaceutically acceptable salt thereof; or a mutant Flt3 inhibitor or a pharmaceutically acceptable salt thereof.
[0077] In one embodiment of the method of the invention or the compound for use of the invention, the cancer is a frontline cancer. In another embodiment, the frontline cancer is a solid tumor cancer. In another embodiment, the frontline cancer is a hematological malignancy. In another embodiment, the frontline hematological malignancy is a frontline AML.
[0078] In another embodiment of the methods of the invention or the compounds for use of the invention, the cancer is a recurrent cancer. In another embodiment, the recurrent cancer is a solid tumor cancer. In another embodiment, the recurrent cancer is a hematological malignancy. In another embodiment, the recurrent hematological malignancy is a recurrent AML.
[0079] In another embodiment of the methods of the invention or compounds for use of the invention, the cancer is a refractory cancer. In another embodiment, the refractory cancer is a solid tumor cancer. In another embodiment, the refractory cancer is a hematological malignancy. In another embodiment, the refractory hematological malignancy is refractory AML.
[0080] In another embodiment of the methods of the invention or the compounds for use of the invention, the cancer is an advanced cancer. In another embodiment, the advanced cancer is an advanced solid tumor cancer. In another embodiment, the advanced cancer is an advanced hematological malignancy. In another embodiment, the advanced hematological malignancy is advanced AML.
[0081] In another embodiment, AML is acute promyelocytic leukemia.
[0082] Methods for determining mutant IDH1 enzymatic activity are known to those of ordinary skill in the art, for example in WO2018 / 111707 Al.
[0083] As used above, and throughout the description of the present invention, unless otherwise indicated, the following terms shall be understood to have the following meanings:
[0084] The term "hematological tissue" refers to blood, bone marrow, spleen, lymph nodes, or lymph fluid.
[0085] The term "solid tumor tissue" refers to tissue that is not hematological tissue. Non-limiting examples of solid tissue are bile duct tissue, pancreatic tissue, head tissue, neck tissue, liver tissue, skin tissue, astrocytoma tissue, oligodendroglial tissue, glial tissue, brain tissue, bladder tissue, colorectal tissue, lung tissue, and nasal sinus undifferentiated carcinoma tissue.
[0086] The term "solid tumor cancer" refers to cancers that originate in tissues other than the blood or bone marrow.
[0087] The term "hematological malignancies" refers to cancers in the blood, bone marrow, lymph nodes, or lymph fluid.
[0088] The term "first line cancer" means that the human cancer subject has never been treated for the cancer being treated.
[0089] The term "refractory cancer" refers to a cancer that has been treated but does not respond to the treatment in a human cancer subject.
[0090] The term "recurrent cancer" refers to a human cancer subject that has responded to treatment for a period of time, but the cancer has returned.
[0091] The term "advanced cancer" refers to cancer that has spread to the lymph nodes or to other tissues beyond the point where the cancer originated. For example, AML is AML that has spread to tissues outside the blood or bone marrow.
[0092] The term "cancer subject" refers to a subject who has been diagnosed with cancer.
[0093] The term "solid tumor subject" refers to a subject who has been diagnosed with a solid tumor cancer. In one embodiment, the solid tumor cancer is bile duct cancer.
[0094] The term "hematological malignancy subject" refers to a subject who has been diagnosed with a hematological malignancy. In one embodiment, the hematological malignancy subject is an AML subject. The term "AML subject" refers to a subject who has been diagnosed with AML. Methods for diagnosing AML are known to those of ordinary skill in the art, for example, in Dohner H et al., Blood 2017; 129: 424-447.
[0095] The terms "acute myeloid leukemia," "acute myelogenous leukemia," and "acute non-lymphocytic leukemia" are synonymous.
[0096] "Responsiveness to treatment of a hematologic malignancy (e.g., AML)" includes improved overall survival, partial response, long-term stable disease, or improvement in long-term survival, characterized by complete remission (determined by less than 5% myeloblasts in the bone marrow, absence of circulating blasts), hematologic recovery (demonstrated by a peripheral blood absolute neutrophil count greater than 1,000 cells / μL and a platelet count greater than 100,000 / μL, no requirement for red blood cell transfusions, and absence of extramedullary disease) (Bloomfield CD et al., Blood Revs. 2018; 32:416-425).
[0097] The term "IDH1 R132 mutation" is synonymous with "R132 IDH1 mutation" and refers to an IDH1 mutation at amino acid residue 132 in an IDH1 gene of a subject, as determined, for example, in nucleic acid (eg, DNA) of the subject.
[0098] The term "Flt3 mutation" refers to a mutation in the Flt3 gene of a subject.
[0099] The term "mutant IDH inhibitor" refers to a compound that inhibits mutant IDH enzyme activity and / or inhibits 2-HG production by mutant IDH enzymes. Methods for determining mutant IDH1 and mutant IDH2 enzyme activity are known to those of ordinary skill in the art, for example in WO 2018 / 111707 A1. In the term "mutant IDH inhibitor", the word "mutant" refers to the IDH gene, not the inhibitor.
[0100] The term "mutant Flt3 inhibitor" refers to a compound that inhibits mutant F13 kinase activity. Methods for determining mutant Flt3 activity are known to those of ordinary skill in the art, for example, in Lee HJ et al., Oncotarget 2018; 9: 924-936. In the term "mutant Flt3 inhibitor", the word "mutant" refers to the Flt3 protein, not the inhibitor compound.
[0101] The term "identified as having an IDH mutation," e.g., an IDH1 or IDH2 mutation, means that nucleic acid (e.g., DNA) from a tissue or cell of a human subject has been analyzed to determine whether the human subject has an IDH mutation. In one embodiment, the blood, bone marrow, lymph nodes, lymph fluid, blood cells, bone marrow cells, lymph node cells, or lymph fluid cells of the human subject have been analyzed for IDH mutations. In another embodiment, a solid tissue of a human subject has been analyzed for IDH mutations.
[0102] The term "Bcl-2 inhibitor" is a compound that binds to Bcl-2 and causes cytotoxicity in cancer cells, downregulation of Bcl-2 expression in cancer cells, mitochondrial dysfunction in cancer cells, and apoptosis in cancer cells. Methods for determining those effects are known to those of ordinary skill in the art, for example, in Wen M et al., Front. Pharmacol. 2019; 10: 391.
[0103] In one embodiment of the methods of the invention, the party that identifies the human subject as having an IDH1 R132 mutation may be different from the party that administers the first and second compounds. In another embodiment, the party that identifies the human subject as having an IDH1 R132 mutation is different from the party that administers the first and second compounds. In another embodiment, the party that identifies the human subject as having an IDH1 R132 mutation is the same as the party that administers the first and second compounds.
[0104] The term "identified as having a Flt3 mutation" means that nucleic acid (eg, DNA) from blood cells, bone marrow cells, or blood and bone marrow cells from a human subject has been analyzed to determine whether the human subject has one or more Flt3 mutations.
[0105] Analytical methods for identifying IDH1 and Flt3 mutations are known to those of ordinary skill in the art (Clark, O. et al., Clin. Cancer. Res. 2016; 22: 1837-42), including but not limited to karyotyping (Guller JL et al., J. Mol. Diagn. 2010; 12: 3-16), fluorescence in situ hybridization (Yeung DT et al., Pathology 2011; 43: 566-579), Sanger sequencing (Lutha, R et al., Haematologica 2014; 99: 465-473), metabolic profiling (Miyata S et al., Scientific Reports 2019; 9: 9787), polymerase chain reaction (Ziai, JM and AJ Siddon, Am. J. Clin. Pathol 2015; 144: 539-554) and next generation sequencing (e.g., whole transcriptome sequencing) (Lutha, R et al., Haematologica 2014;99:465-473; Wang HY et al., J. Exp. Clin. Cancer Res. 2016;35:86).
[0106] The terms "treatment," "treat," "treating," and the like are intended to include slowing, stopping, or reversing the progression of a cancer. These terms also include alleviating, ameliorating, attenuating, eliminating, or reducing one or more symptoms of a disorder or condition, even if the cancer is not actually eliminated and even if the progression of the cancer itself is not slowed, stopped, or reversed.
[0107] "Therapeutically effective amount" refers to an amount of a compound or a pharmaceutically acceptable salt thereof administered to a subject that will elicit a biological or medical response in the subject or a desired therapeutic effect on the subject.
[0108] As a person skilled in the art, the attending physician can readily determine the therapeutically effective amount by using known techniques and by observing the results obtained under similar circumstances. In determining the effective amount for a subject, the attending physician considers many factors, including, but not limited to: the size, age, and general health of the individual subject; the specific disease or condition involved; the extent or severity of the disease or condition involved; the response of the individual subject; the specific compound being administered; the mode of administration; the bioavailability characteristics of the administered formulation; the dosage regimen selected; concomitant medications used; and other relevant circumstances.
[0109] The term "in combination with" means the use of a compound of Formula I or a compound of Formula I for simultaneous, separate or sequential combination with any one or more of antimetabolites or pharmaceutically acceptable salts thereof; a hypomethylating agent or a pharmaceutically acceptable salt thereof, optionally in combination with a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof; or a mutant Flt3 inhibitor or a pharmaceutically acceptable salt thereof, in the treatment of cancer in a human subject having an IDH mutation.
[0110] The compounds administered by the methods of the present invention may optionally be formulated into pharmaceutical compositions that are administered by any route that makes the compound bioavailable. In one embodiment, such compositions are formulated for oral administration. Such pharmaceutical compositions and methods for their preparation are well known in the art. (See, for example, Remington: The Science and Practice of Pharmacy (DB Troy, Editor, 21st edition, Lippincott, Williams & Wilkins, 2006).
[0111] A "pharmaceutically acceptable carrier, diluent or excipient" is a medium generally accepted in the art for delivering a biologically active agent to a mammal (eg, a human).
[0112] It will be appreciated by those of ordinary skill in the art that the compounds administered in the methods of the present invention are capable of forming salts. The compounds react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Such pharmaceutically acceptable acid addition salts and common methods for preparing them are well known in the art. See, for example, P. Stahl et al., HANDBOOKOF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA / Wiley-VCH, 2008).
[0113] "Pharmaceutically acceptable salt" or "pharmaceutically usable salt" refers to a relatively non-toxic inorganic or organic salt or salts of a compound of this invention (SM Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977).
[0114] Materials and methods
[0115] Compounds and formulations: For in vivo studies, each test article was prepared with a vehicle at an appropriate concentration. For in vivo studies, Compound A was formulated in an Acacia vehicle (water, 10% Acacia, 0.05% defoamer [Dow Corning 1510-US]) with 1.1 molar equivalents of HCl. Compound A was freshly prepared with a vehicle at an appropriate concentration every 7 days and stored at 4°C between dosing. Midostaurin (Medchem Express, batch / lot number Lot#23950) was formulated in a 20% PEG400 aqueous solution and freshly prepared weekly (stored at 4°C between dosing). Cytarabine was freshly prepared weekly by diluting a stock solution of cytarabine (injection 20 mg / mL, (Pfizer injection)) with sterile saline. Azacitidine (Sigma, batch number MKBR7212) was prepared in sterile water and freshly prepared daily immediately before dosing.
[0116] In vivo human AML PDx model: AML models were established after tail vein injection of primary human AML cells into female NOD SCIDγ (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ [Jackson Labs #005557]) mice (6 to 7 weeks old). Two models were used in the study: 1) IDH1(R132H), NRas(Q61H) primary human AML and (2) IDH1(R132H), Flt3-ITD primary human AML. Splenocytes from tumor-bearing mice were used to propagate and expand the model as described, as needed. Each test article was prepared with vehicle at an appropriate concentration as described above, and the animals were given the doses tested in this study at a dosing volume of 10 μL / gram body weight. Mice receiving Compound A (PO, QD) were treated at the indicated doses during this study. The combination was administered as follows: midostaurin 50 mg / kg PO, QD (53 days, starting 7 days after the start of Compound A dosing), cytarabine 2 mg / kg IP [(QD×5, rest 2)×2] rest 14d and repeat (2 cycles, starting at the start of Compound A dosing), azacitidine 1 mg / kg IP [(QD×5, rest 2)×2] rest 14d and repeat (2 cycles, starting at the start of Compound A dosing). (tumor-free) control mice were compared to the treated mice. Body weight was recorded twice a week. Whole blood samples (<100 μL) were collected into K-EDTA blood collection tubes every two weeks during the study by submandibular bleeding and analyzed by FACS to monitor the differentiation state and leukemia load in the study mice (plasma was regularly collected for 2-HG analysis during the study). For plasma collection, for each subject, 50 to 70 μL of whole blood was aliquoted into 1.5 mL microcentrifuge tubes and spun at 300 x g for 8 minutes (4 ° C). 10 μL of plasma was collected and transferred to a new 1.5 mL microcentrifuge tube and frozen at -80 ° C for 2-HG LCMS analysis. Plasma 2-HG was evaluated by using plasma from the vehicle-treated and untreated mice as controls to monitor the inhibition of 2-HG production. For flow cytometry, 50-70 μL of whole blood was collected, 60 μL of staining / washing buffer (5% heat-inactivated (HI)-FBS (v / v) (Invitrogen 10082) in DPBS (Hyclone SH30028) was added to each tube, mixed by pipetting up and down 3 to 4 times, and 100 μL of blood suspension was transferred to a 5 mL polypropylene tube, stained and analyzed as described below.
[0117] AML PDx Model Propagation: Mice engrafted with human IDH1(R132H) AML cells were identified as having advanced disease progression in the patient-derived IDH1(R132H) leukemia model by flow cytometry of whole blood samples. Spleens were processed and splenocytes isolated as described below. 200 μL / subject splenocyte preparations were injected IV (intravenously, tail vein) into recipient NSG mice. (10e 6 -25e 6 live leukocytes / mL, 2e per mouse 6 -5e 6 For propagation models). Progress was monitored by flow cytometric analysis every four weeks until AML (>0.2% human AML cells (% hCD33+hCD45+ of total white blood cells (WBC)) was identified in peripheral blood. Once engraftment was confirmed, mice were monitored every two weeks until ready for study. Mice were randomized and studies were initiated when the average % human AML (of total WBC) reached 2-8%. Submandibular blood was collected.
[0118] Spleen / spleen cell processing and preparation: After excision, the spleen was weighed, and 3 / 4 of the spleen was placed in a standard sterile 15mL polypropylene conical tube containing PBS and placed on ice. The remaining 1 / 4 of the spleen was fixed in 10% NBF and delivered to pathology. The spleen was placed in ice-cold sterile PBS in a 15mL collection tube. The spleen was removed from the collection tube and placed in a 100 micron 50mL conical tube cell filter (BD Falcon#352360). The spleen was processed by gently rubbing the spleen tissue against the surface of the cell filter in a circular motion with the end of a 5ml syringe plunger. During this process, the surface of the filter was rinsed 3 times with 10ml room temperature sterile DPBS (Hyclone SH30028). After no complete spleen tissue was visible, the final rinse of the filter was performed, and the cell preparation was mixed up and down 15 times using a 10mL sterile serological pipette. The cell pellet was collected by centrifugation (300×g) and washed three times with 30mL sterile DPBS. The cells were counted and resuspended in DPBS at the desired implant concentration.
[0119] Bone marrow collection: Bone marrow was collected from tibiae and femurs using a 27G to 25G needle in a 1 mL syringe containing 1 mL PBS.
[0120] Flow cytometric analysis of human leukocytes: Submandibular blood samples were collected from in vivo studies. Fluorescent-conjugated antibody stains (anti-human CD33-PE (clone WM53, BD catalog number 555450), anti-human CD14-APC (clone BD catalog number 340436), anti-human CD15-V450 (clone HI98, BD catalog number 561584), anti-human CD117-BV421 (clone YB5.B8, BD catalog number 562434), anti-human CD11b-APCCy7 (clone ICRF44, BD catalog number 557754), anti-human CD45-PECy7 (clone HI30, BD catalog number 557748) and anti-human CD3-FITC (clone SK7, BD catalog number 340542)). The samples were incubated at room temperature in the dark for 30 minutes. After incubation, 1.5 mL 1X BD Lyse / Fix (37°C, (BD#558049)) was added to each sample and incubated at room temperature for 12 minutes. The tube was centrifuged at 300×g for 7 minutes. Aspirate BD Lyse / Fix solution, and wash the cell pellet 3 times with staining / washing buffer (1 washing step consists of: resuspending the pellet in 3mL staining / washing buffer, centrifuging at 300x g, and aspirating washing). The fixed cells are then resuspended in 300 to 400 μL staining / washing buffer. Samples are analyzed on a BectonDickinson FACSVerse flow cytometer (Catalog No. 651155 Serial No. Z6511550447) using standard flow cytometry principles and techniques. Analyze samples on the same day of staining and fixing samples. Data analysis of population gating and population percentages is performed on a FACSVerse cell counter with FACSuite software. Population percentage values from data analysis are plotted in GraphPad Prism or JMP13. If an animal dies of disease or if blood cannot be obtained on any given day due to technical reasons, there will be no data points on that day, so it is uncertain (ND).
[0121] LC-MS metabolite analysis in plasma of AML PDx models: The effect of IDH1 inhibition on total 2-HG and α-KG concentrations was determined by liquid chromatography-mass spectrometry (LC-MS) analysis of plasma. Calibration curves were prepared by spiking 2-HG and α-KG into water. The method utilized O-benzylhydroxylamine derivatization prior to analysis by LC-MS. 10 microliters of each standard or sample was placed in a deep-well 96-well plate and combined with 100 μL of an internal standard solution containing 10 μM d5-3-hydroxyglutaric acid and 10 μM d6-α-KG. The plasma samples were then treated with 210 μl of 4:3 methanol:chloroform, centrifuged, and the supernatant removed and dried. 100uL of 1M O-benzyl-hydroxylamine in pyridine buffer (8.6% pyridine, pH 5) and 100uL of 1M N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) in pyridine buffer were added to each sample. The derivatization reaction was carried out at room temperature for 1 hour. Using a Beckman Biomek FX liquid handler, 300μL of ethyl acetate was added to each sample. The plate was sealed and vortexed for 5 minutes, then centrifuged at 4000rpm for 5 minutes in an Eppendorf 5810R centrifuge. 220μL of the upper layer was transferred to a new 96-well plate. The sample was dried at 50°C under heated nitrogen and reconstituted with 100μL methanol / water (1:1). One microliter of the derivatized sample was injected into a Shimadzu Prominence 20A HPLC system and a Thermo Quantum Ultra TM On a LC-MS system consisting of a triple quadrupole mass spectrometer. TM The analytes were separated on a C18 column (2.1 x 50 mm, 3.5 μm) at a flow rate of 0.6 mL / min. Mobile phase A was 0.1% formic acid in water and mobile phase B was methanol. The gradient profile was: 0 min, 5% B; 2 min, 100% B; 4.00 min, 100% B; 4.1 min, 5% B; 5.50 min, stop. The mass spectrometer utilized a HESI-II probe operated in positive ion selective reaction monitoring mode. The analyte concentration was plotted versus the analyte / internal standard peak area ratio and weighted using 1 / concentration, using Xcalibur TM The software performs a quadratic fit of the data to construct a calibration curve. The analyte concentrations of the unknowns are back-calculated from the calibration curve.
[0122] Statistical methods
[0123] Combination Analysis Method (BlissIndependence for IVEF study) can be used to analyze the results. The usual repeated measures model is fitted to log volume vs. group and time. Contrast statements are used to test the interaction effect of two specific treatments in combination at each time point. This is equivalent to the Bliss Independence method and assumes that the tumor volume can theoretically reach zero, i.e. complete regression.
[0124] The expected additive response (EAR) of the combination was calculated on a tumor volume scale as: Response (EAR) EAR Volume = V1*V2 / V0, where V0, V1, and V2 are the estimated mean tumor volumes of vehicle control, treatment 1 alone, and treatment 2 alone, respectively. If the interaction test is significant, the combination effect is statistically declared greater than additive or less than additive, depending on whether the observed combined mean volume is less than or greater than the EAR volume, respectively. Otherwise, the statistical conclusion is additive.
[0125] If stasis is the best expected response, the Bliss method can be applied directly to the %ΔT / C values to obtain the EAR percent response: EAR %ΔT / C = Y1*Y2 / 100, where Y1 and Y2 are the percent ΔT / C values for the single agent treatments.
[0126] 1. Combination of Compound A and Cytarabine
[0127] In experiments performed essentially as described above, the results in Tables 1A-1D were obtained for the combination of Compound A and cytarabine.
[0128]
[0129] Each column is data from one animal.
[0130] On day 47, the % plasma AML cells for each corresponding treatment group were: A: vehicle (86%); B: Compound A (39%); C: cytarabine (5.2%); and E: Compound A + cytarabine (0.48%) (p<0.001).
[0131]
[0132] Each column is data from one animal.
[0133] At day 47, the % AML cell differentiation for each corresponding treatment group was: A: vehicle (10%); B: Compound A (37%); C: cytarabine (8%); and E: Compound A + cytarabine (71%) (p<0.001).
[0134]
[0135] For each corresponding treatment group, the % bone marrow AML clearance rates were: A: Vehicle (94%); B: Compound A (78%); C: Cytarabine (63%); and Compound A + Cytarabine (14%) (p=0.0011).
[0136]
[0137]
[0138] For each corresponding treatment group, % plasma 2-HG was: A: Vehicle (100%); B: Compound A (3.4%); C: Cytarabine (24%); and E: Compound A + Cytarabine (11%) (p=0.0004).
[0139] In conclusion, the combination of Compound A and cytarabine enhanced the suppression of AML both in the bone marrow and in the periphery.
[0140] 2. Combination of Compound A and Azacitidine
[0141] In experiments performed essentially as described above, the results in Tables 2A-2D were obtained for the combination of Compound A and azacitidine.
[0142]
[0143]
[0144] Each column is data from one animal.
[0145] On day 43, the % plasma AML cells for each corresponding treatment group were: A: vehicle (71%); B: Compound A (52%); G: azacitidine (22%); and H: Compound A + azacitidine (9.7%) (p<0.023).
[0146]
[0147]
[0148] Each column is data from one animal.
[0149] At day 43, the % AML cell differentiation for each corresponding treatment group was: A: vehicle (15%); B: Compound A (37%); G: Azacitidine (10%); and H: Compound A + Azacitidine (59%) (p<0.001).
[0150]
[0151]
[0152] For each corresponding treatment group, % bone marrow AML clearance was: A: Vehicle (94%); B: Compound A (87%); G: Azacitidine (55%); and H: Compound A + Azacitidine (19%) (p=0.0032).
[0153]
[0154]
[0155] For each corresponding treatment group, % plasma 2-HG was: A: Vehicle (100%); B: Compound A (-15%); G: Azacitidine (48%); and H: Compound A + Azacitidine (-9.6%) (p=0.1714).
[0156] In conclusion, the combination of Compound A and azacitidine enhanced the suppression of AML both in the bone marrow and in the periphery.
[0157] 3. Combination of Compound A and Midostaurin
[0158] In experiments performed essentially as described above, the results obtained for the combination of Compound A and midostaurin
[0159] Results in Tables 3A-D.
[0160]
[0161]
[0162] Each column is data from one animal.
[0163] On day 50, the % plasma AML cells for each corresponding treatment group were: A: vehicle (32%); B: 1 mg Compound A (37%); F: midostaurin (1.1%); and I: 1 mg Compound A + midostaurin (2.2%) (p=0.473).
[0164] On day 50, the % plasma AML cells for each corresponding treatment group were: A: vehicle (32%); C: 10 mg Compound A (2.8%); F: midostaurin (1.1%); and L: 10 mg Compound A + midostaurin (0.6%) (p=0.016).
[0165] On day 64, the % plasma AML cells for each corresponding treatment group were: A: vehicle (67%); B: 1 mg Compound A (51%); F: midostaurin (2.2%); and I: 1 mg Compound A + midostaurin (1.3%) (p=0.767).
[0166] On day 64, the % plasma AML cells for each corresponding treatment group were: A: vehicle (67%); C: 10 mg Compound A (1.1%); F: midostaurin (2.2%); and L: 10 mg Compound A + midostaurin (0.56%) (p<0.001).
[0167] On day 78, the % plasma AML cells for each corresponding treatment group were: A: vehicle (129%); B: 1 mg Compound A (65%); F: midostaurin (3.9%); and I: 1 mg Compound A + midostaurin (1.6%) (p=0.829).
[0168] On day 78, the % plasma AML cells for each corresponding treatment group were: A: vehicle (129%); C: 10 mg Compound A (0.66%); F: midostaurin (3.9%); and L: 10 mg Compound A + midostaurin (0.25%) (p<0.001).
[0169]
[0170]
[0171] Each column is data from one animal.
[0172] At day 50, the % AML cell differentiation for each corresponding treatment group was: A: vehicle (28%); B: 1 mg Compound A (43%); F: midostaurin (33%); and I: 1 mg Compound A + midostaurin (81%) (p<0.001).
[0173] At day 50, the % AML cell differentiation for each corresponding treatment group was: A: vehicle (28%); C: 10 mg Compound A (79%); F: midostaurin (33%); and L: 10 mg Compound A + midostaurin (80%) (p 0.776).
[0174]
[0175]
[0176] For each corresponding treatment group, the % bone marrow AML clearance rates were: A: Vehicle (86%); B: 1 mg Compound A (90%); F: Midostaurin (26%); and I: 1 mg Compound A + Midostaurin (19%) (p=0.828).
[0177] For each corresponding treatment group, the % bone marrow AML clearance rates were: A: vehicle (86%); C: 10 mg Compound A (2.3%); F: midostaurin (26%); and L: 1 mg Compound A + midostaurin (0.58%) (p=0.906).
[0178]
[0179]
[0180] For each corresponding treatment group, % plasma 2-HG was: A: vehicle (100%); B: 1 mg Compound A (38%); F: midostaurin (70%); and I: 1 mg Compound A + midostaurin (21%) (p=0.789).
[0181] For each corresponding treatment group, % plasma 2-HG was: A: vehicle (100%); C: 10 mg Compound A (9.2%); F: midostaurin (70%); and L: 10 mg Compound A + 10 mg midostaurin (6.8%) (p=0.373).
[0182] In conclusion, the combination of Compound A and midostaurin enhanced the suppression of AML both in the bone marrow and in the periphery.
Claims
1. A compound of the formula: Use of a combination of tadalafil or a pharmaceutically acceptable salt thereof and azacitidine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating acute myeloid leukemia in a human subject having an IDH mutation.
2. The use according to claim 1, wherein the IDH mutation is an IDH1 mutation.
3. The use according to claim 2, wherein the IDH1 mutation is an IDH1 R132 mutation.
4. The use of claim 1, wherein the IDH mutation is an IDH2 mutation.
5. The use according to claim 4, wherein the IDH2 mutation is an IDH2 R140 or IDH2 R172 mutation.
6. The method of claim 1, wherein the compound is:
7. The use according to any one of claims 1 to 6, wherein the compound is combined with azacitidine or a pharmaceutically acceptable salt thereof, and further combined with a Bcl-2 inhibitor, wherein the Bcl-2 inhibitor is venetoclax or a pharmaceutically acceptable salt thereof.
